AHA 2022 Top Data Review


Our editorial team has compiled a list of the top data and news from the American Heart Association 2022 Scientific Sessions, with a focus on heart failure, hypertension, and lipid management.

Top Heart Failure News from AHA 2022

Heart failure and the evolving field of cardiorenal metabolism have stolen the show at most major cardiology conferences and congresses in the past half decade. AHA 2022 was no different. Among the bevy of abstracts and sessions dedicated to cardiometabolic health were data related to TRANSFORM-HF, STRONG-HF, and EMPA-KIDNEY. In the special AHA 2022 edition of Don’t Miss a Beat, hosts Muthiah Vaduganathan, MD, MPH, and Stephen Greene, MD, explore the TRANSFORM-HF trial, which Greene served on as an investigator, and the EMPA-Kidney trial.

Torsemide Provides No Benefit Over Furosemide for Mortality, Hospitalization in Heart Failure

Results of the TRANSFORM-HF trial presented at AHA 22 indicate there were no significant differences in rate of all-cause mortality or hospitalization with the use of torsemide compared with furosemide in people with heart failure.

STRONG-HF: In-Hospital Initiation of GDMT Reduces Rehospitalization, Mortality Risk in Heart Failure Patients

Results of the STRONG-HF trial provide the first evidence from a randomized clinical trial that rapid, in-hospital initiation of guideline-directed medical therapy in heart failure can improve patient outcomes.

Don't Miss a Beat: AHA 2022

In this episode of Don't Miss a Beat, hosts Muthiah Vaduganathan, MD, MPH, and Stephen Greene, MD, are bringing you insights from the AHA 2022 Scientific Sessions. In the episode, which was recorded on day 2 of the 3-day meeting, our hosts offer listeners perspective on the EMPA-KIDNEY and the TRANSFORM-HF trial.

Top Hypertension News from AHA 2022

A cornerstone in management and prevention of cardiovascular disease, achieving optimal blood pressure management on a population level has eluded cardiologists and health care providers despite progress against cardiovascular disease rates. At AHA 2022, hypertension was in the spotlight with multiple studies examining different approaches to management in various patient populations, including late-breaking data from the

Hydrochlorothiazide as Effective as Chlorthalidone for Preventing CVD, Death in Hypertension

Data from the Diuretic Comparison Project suggests chlorthalidone did not provide a reduction in cardiovascular risk or all-cause mortality compared with use of hydrochlorothiazide in older patients with hypertension.

Phase 2 Data Shows Promise for Baxdrostat in Treatment-Resistant Hypertension

Phase 2 data from the BrigHTN trial suggest use of 2 mg baxdrostat was associated with significantly and substantially reduced systolic and diastolic blood pressure in patients with treatment-resistant hypertension. In a Q&A, trial investigator Deepak Bhatt, MD, MPH, provides further insight.

Many Older Adults Not Receiving Adequate Hypertensive Therapy, with Deepak Bhatt, MD, MPH

An analysis of nationally representative data from AHA 2022 suggests most older adults in the US with hypertension were not receiving adequate treatment intensification set forth in US and international guidelines.

Pooled Data from RADIANCE Demonstrates Ability of Denervation to Lower Blood Pressure

A pooled analysis of data from the RADIANCE-HTN TRIO, RADIANCE-HTN SOLO, and RADIANCE II trials provide a comprehensive overview of the potential reductions in blood pressure possible with renal denervation.

Top Lipid Management News from AHA 2022

Few fields in cardiovascular care have seen the rapid growth in knowledge and pharmacology as lipid management in the past decade. As the understanding of lipid management grows, so have therapies, with new agents developed to lower triglycerides and Lp(a). At AHA 2022, a multitude of studies and trials provided the community with further insight into the effects of various agents on LDL-C, Lp(a), and triglycerides across various patient populations. In an episode of The Heart Team podcast, Aruna Pradhan, MD, MPH, discusses the results of the PROMINENT trial and the role of triglyceride reduction.

SPORT: Supplements Fail to Lower LDL-C in Primary Prevention Population

Erin Michos, MD, provides further insight in an on-site interview AHA 22 related to results of the SPORT trial, which provide direct comparative insights into the impact of several dietary supplements and placebo therapy relative to low-dose statin therapy in a primary prevention cohort.

Ocean(a)-DOSE: Olpasiran Shows Promise for Lowering Lipoprotein(a)

Results of the Ocean(a)-DOSE trial, a phase 2 dose-finding study presented at AHA 22, suggests use of olpasiran dosed at 75 mg or higher every 12 weeks was associated with a reduction of Lp(a) among 95% of patients.

Pemafibrate Did Not Reduce Risk of Cardiovascular Events in PROMINENT Trial

The late-breaking findings presented at AHA 2022 suggest the incidence of CV events was not lower among patients who received pemafibrate compared with those who received placebo.

EPA Reaches Borderline Statistical Significance in RESPECT-EPA Trial

The late-breaking findings suggest the potential prognostic benefit of highly purified EPA in patients with chronic CAD with a low EPA/AA ratio.

The Heart Team at AHA 2022: PROMINENT Results and Triglycerides, with Aruna Pradhan, MD, MPH

Aruna Pradhan, MD, MPH, joins The Heart Team at AHA 2022 to discuss the design, results, and her interpretation of the PROMINENT trial for practicing clinicians as well as how she interprets use of triglyceride-lowering agents in the wake of PROMINENT and RESPECT-EPA results.

Related Videos
HCPLive Five at ACC 2024 | Image Credit: HCPLive
Ankeet Bhatt, MD, MBA | Credit: X.com
Ankeet Bhatt, MD, MBA | Credit: X.com
Sara Saberi, MD | Credit: University of Michigan
Muthiah Vaduganathan, MD, MPH | Credit: Brigham and Women's Hospital
Albert Foa, MD, PhD | Credit: HCPLive
Veraprapas Kittipibul, MD | Credit: X.com
Heart Failure stock imagery. | Credit: Fotolia
© 2024 MJH Life Sciences

All rights reserved.